Use of mesenchymal stem cells as treatment for graft-versus-host disease: current knowledge and controversies

Immunotherapy ◽  
2011 ◽  
Vol 3 (6) ◽  
pp. 701-704 ◽  
Author(s):  
Miguel Ortín ◽  
Jorge Sierra
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Graft Versus Host Disease ◽  
Current Knowledge ◽  
Host Disease ◽  
Graft Versus Host

Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells

The Lancet ◽  
2004 ◽  
Vol 363 (9419) ◽  
pp. 1439-1441 ◽  
Author(s):  
Katarina Le Blanc ◽  
Ida Rasmusson ◽  
Berit Sundberg ◽  
Cecilia Götherström ◽  
Moustapha Hassan ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Graft Versus Host Disease ◽  
Third Party ◽  
Host Disease ◽  
Graft Versus Host ◽  
Acute Graft

Mesenchymal Stem Cells Attenuate Rat Graft-Versus-Host Disease

2014 ◽  
pp. 341-353 ◽  
Author(s):  
Masayuki Fujino ◽  
Ping Zhu ◽  
Yusuke Kitazawa ◽  
Ji-Mei Chen ◽  
Jian Zhuang ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Graft Versus Host Disease ◽  
Host Disease ◽  
Graft Versus Host

scholarly journals Glutathione dynamics determine the therapeutic efficacy of mesenchymal stem cells for graft-versus-host disease via CREB1-NRF2 pathway

2020 ◽  
Vol 6 (16) ◽  
pp. eaba1334 ◽  
Author(s):  
Jisun Lim ◽  
Jinbeom Heo ◽  
Hyein Ju ◽  
Ji-Woong Shin ◽  
YongHwan Kim ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Graft Versus Host Disease ◽  
Target Genes ◽  
Cellular Immunotherapy ◽  
Humanized Mouse Model ◽  
Host Disease ◽  
Nrf2 Pathway ◽  
Graft Versus Host ◽  
Nonprotein Thiol

Glutathione (GSH), the most abundant nonprotein thiol functioning as an antioxidant, plays critical roles in maintaining the core functions of mesenchymal stem cells (MSCs), which are used as a cellular immunotherapy for graft-versus-host disease (GVHD). However, the role of GSH dynamics in MSCs remains elusive. Genome-wide gene expression profiling and high-throughput live-cell imaging assays revealed that CREB1 enforced the GSH-recovering capacity (GRC) of MSCs through NRF2 by directly up-regulating NRF2 target genes responsible for GSH synthesis and redox cycling. MSCs with enhanced GSH levels and GRC mediated by CREB1-NRF2 have improved self-renewal, migratory, anti-inflammatory, and T cell suppression capacities. Administration of MSCs overexpressing CREB1-NRF2 target genes alleviated GVHD in a humanized mouse model, resulting in improved survival, decreased weight loss, and reduced histopathologic damages in GVHD target organs. Collectively, these findings demonstrate the molecular and functional importance of the CREB1-NRF2 pathway in maintaining MSC GSH dynamics, determining therapeutic outcomes for GVHD treatment.

Sign in / Sign up

Export Citation Format

Share Document